Spirocyclic tetrahydroquinazolines
US11312724B2 · kind B2 · utility
3Cited by
0References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 12, 2021 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Mar 12, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure provides compounds represented by Formula I: wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.